Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, with a five-year survival rate of just 13%. For the >80% of patients presenting with metastatic disease, standard-of-care systemic chemotherapies such as FOLFIRINOX or gemcitabine/nab-paclitaxel (GnP) inevitably induce resistance, frequently forci...
Brooke A. Pereira, Katie A. Gordon, Victoria M. Tyma et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal and metastatic malignancy, with standard-of-care treatments, such as gemcitabine/nab-paclitaxel (GnP) offering limited improvement for patients with advanced disease. We and others have shown that co-targeting key factors in combination with chemotherapy...
Shona Ritchie, Victoria M. Tyma, Shanna Hafiz et al.· Cancer Research· 0 citations
In patient derived models of pancreatic cancer, it is demonstrated that priming with KD025 disrupts the extracellular matrix whilst also reducing overall metastatic spreading and burden in this disease.
Niamh E. P. Mills, K. Murphy, Lily M. Channon et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.